Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy

Joseph I. Friedman, Jean Pierre Lindenmayer, Frances Alcantara, Stephanie Bowler, Mohan Parak, Leonard White, Adel Iskander, Michael Parrella, David N. Adler, Nicholas D. Tsopelas, Wei Yann Tsai, Vladan Novakovick, Philip D Harvey, Kenneth L. Davis

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics. This lack of complete success has prompted the frequent use of various clozapine combination strategies despite a paucity of evidence from randomized controlled trials supporting their efficacy. Pimozide, a diphenylbutylpiperidine, possesses pharmacological and clinical properties distinct from other typical antipsychotics. An open-label trial of pimozide adjunctive treatment to clozapine provided promising pilot data in support of a larger controlled trial. Therefore, we conducted a double-blind, placebo-controlled, parallel-designed 12-week trial of pimozide adjunctive treatment added to ongoing optimal clozapine treatment in 53 patients with schizophrenia and schizoaffective disorder partially or completely unresponsive to clozapine monotherapy. An average dose of 6.48 mg/day of pimozide was found to be no better than placebo in combination with clozapine at reducing Positive and Negative Syndrome Scale total, positive, negative, and general psychopathology scores. There is no suggestion from this rigorously conducted trial to suggest that pimozide is an effective augmenting agent if an optimal clozapine trial is ineffective. However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted.

Original languageEnglish
Pages (from-to)1289-1295
Number of pages7
JournalNeuropsychopharmacology
Volume36
Issue number6
DOIs
StatePublished - May 1 2011

Fingerprint

Pimozide
Clozapine
Psychotic Disorders
Inpatients
Schizophrenia
Antipsychotic Agents
Placebos
Psychopathology
Therapeutics
Randomized Controlled Trials
Pharmacology

Keywords

  • clozapine
  • combination
  • pimozide
  • schizophrenia
  • treatment non-response

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Friedman, J. I., Lindenmayer, J. P., Alcantara, F., Bowler, S., Parak, M., White, L., ... Davis, K. L. (2011). Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology, 36(6), 1289-1295. https://doi.org/10.1038/npp.2011.14

Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. / Friedman, Joseph I.; Lindenmayer, Jean Pierre; Alcantara, Frances; Bowler, Stephanie; Parak, Mohan; White, Leonard; Iskander, Adel; Parrella, Michael; Adler, David N.; Tsopelas, Nicholas D.; Tsai, Wei Yann; Novakovick, Vladan; Harvey, Philip D; Davis, Kenneth L.

In: Neuropsychopharmacology, Vol. 36, No. 6, 01.05.2011, p. 1289-1295.

Research output: Contribution to journalArticle

Friedman, JI, Lindenmayer, JP, Alcantara, F, Bowler, S, Parak, M, White, L, Iskander, A, Parrella, M, Adler, DN, Tsopelas, ND, Tsai, WY, Novakovick, V, Harvey, PD & Davis, KL 2011, 'Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy', Neuropsychopharmacology, vol. 36, no. 6, pp. 1289-1295. https://doi.org/10.1038/npp.2011.14
Friedman, Joseph I. ; Lindenmayer, Jean Pierre ; Alcantara, Frances ; Bowler, Stephanie ; Parak, Mohan ; White, Leonard ; Iskander, Adel ; Parrella, Michael ; Adler, David N. ; Tsopelas, Nicholas D. ; Tsai, Wei Yann ; Novakovick, Vladan ; Harvey, Philip D ; Davis, Kenneth L. / Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. In: Neuropsychopharmacology. 2011 ; Vol. 36, No. 6. pp. 1289-1295.
@article{c86d0c8e154e4f9eab1bde4a51cf3100,
title = "Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy",
abstract = "Despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics. This lack of complete success has prompted the frequent use of various clozapine combination strategies despite a paucity of evidence from randomized controlled trials supporting their efficacy. Pimozide, a diphenylbutylpiperidine, possesses pharmacological and clinical properties distinct from other typical antipsychotics. An open-label trial of pimozide adjunctive treatment to clozapine provided promising pilot data in support of a larger controlled trial. Therefore, we conducted a double-blind, placebo-controlled, parallel-designed 12-week trial of pimozide adjunctive treatment added to ongoing optimal clozapine treatment in 53 patients with schizophrenia and schizoaffective disorder partially or completely unresponsive to clozapine monotherapy. An average dose of 6.48 mg/day of pimozide was found to be no better than placebo in combination with clozapine at reducing Positive and Negative Syndrome Scale total, positive, negative, and general psychopathology scores. There is no suggestion from this rigorously conducted trial to suggest that pimozide is an effective augmenting agent if an optimal clozapine trial is ineffective. However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted.",
keywords = "clozapine, combination, pimozide, schizophrenia, treatment non-response",
author = "Friedman, {Joseph I.} and Lindenmayer, {Jean Pierre} and Frances Alcantara and Stephanie Bowler and Mohan Parak and Leonard White and Adel Iskander and Michael Parrella and Adler, {David N.} and Tsopelas, {Nicholas D.} and Tsai, {Wei Yann} and Vladan Novakovick and Harvey, {Philip D} and Davis, {Kenneth L.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1038/npp.2011.14",
language = "English",
volume = "36",
pages = "1289--1295",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy

AU - Friedman, Joseph I.

AU - Lindenmayer, Jean Pierre

AU - Alcantara, Frances

AU - Bowler, Stephanie

AU - Parak, Mohan

AU - White, Leonard

AU - Iskander, Adel

AU - Parrella, Michael

AU - Adler, David N.

AU - Tsopelas, Nicholas D.

AU - Tsai, Wei Yann

AU - Novakovick, Vladan

AU - Harvey, Philip D

AU - Davis, Kenneth L.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics. This lack of complete success has prompted the frequent use of various clozapine combination strategies despite a paucity of evidence from randomized controlled trials supporting their efficacy. Pimozide, a diphenylbutylpiperidine, possesses pharmacological and clinical properties distinct from other typical antipsychotics. An open-label trial of pimozide adjunctive treatment to clozapine provided promising pilot data in support of a larger controlled trial. Therefore, we conducted a double-blind, placebo-controlled, parallel-designed 12-week trial of pimozide adjunctive treatment added to ongoing optimal clozapine treatment in 53 patients with schizophrenia and schizoaffective disorder partially or completely unresponsive to clozapine monotherapy. An average dose of 6.48 mg/day of pimozide was found to be no better than placebo in combination with clozapine at reducing Positive and Negative Syndrome Scale total, positive, negative, and general psychopathology scores. There is no suggestion from this rigorously conducted trial to suggest that pimozide is an effective augmenting agent if an optimal clozapine trial is ineffective. However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted.

AB - Despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics. This lack of complete success has prompted the frequent use of various clozapine combination strategies despite a paucity of evidence from randomized controlled trials supporting their efficacy. Pimozide, a diphenylbutylpiperidine, possesses pharmacological and clinical properties distinct from other typical antipsychotics. An open-label trial of pimozide adjunctive treatment to clozapine provided promising pilot data in support of a larger controlled trial. Therefore, we conducted a double-blind, placebo-controlled, parallel-designed 12-week trial of pimozide adjunctive treatment added to ongoing optimal clozapine treatment in 53 patients with schizophrenia and schizoaffective disorder partially or completely unresponsive to clozapine monotherapy. An average dose of 6.48 mg/day of pimozide was found to be no better than placebo in combination with clozapine at reducing Positive and Negative Syndrome Scale total, positive, negative, and general psychopathology scores. There is no suggestion from this rigorously conducted trial to suggest that pimozide is an effective augmenting agent if an optimal clozapine trial is ineffective. However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted.

KW - clozapine

KW - combination

KW - pimozide

KW - schizophrenia

KW - treatment non-response

UR - http://www.scopus.com/inward/record.url?scp=79954604460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954604460&partnerID=8YFLogxK

U2 - 10.1038/npp.2011.14

DO - 10.1038/npp.2011.14

M3 - Article

C2 - 21346734

AN - SCOPUS:79954604460

VL - 36

SP - 1289

EP - 1295

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 6

ER -